Drug-conjugated monoclonal antibodies for the treatment of cancer.
about
Synthesis of site-specific antibody-drug conjugates using unnatural amino acidsClinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancerAntibody-drug conjugates as novel anti-cancer chemotherapeuticsImplications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugatesAntibody drug-conjugates targeting the tumor vasculature: Current and future developmentsTargeted Delivery of Deoxycytidine Kinase to Her2-Positive Cells Enhances the Efficacy of the Nucleoside Analog FludarabineIdentification of accessible human cancer biomarkers using ex vivo chemical proteomic strategies.The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer.Targeting of a developmentally regulated epitope of CD43 for the treatment of acute leukemia.The interplay between mutasynthesis and semisynthesis: generation and evaluation of an ansamitocin library.Antibody-DM1 conjugates as cancer therapeutics.Multiple site-specific in vitro labeling of single-chain antibodyOne-component nanomedicineMonoclonal antibodies as therapeutic agents in oncology and antibody gene therapy.Site-specific linking of biomolecules via glycan residues using glycosyltransferases.CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumorsA rapid on-line method for mass spectrometric confirmation of a cysteine-conjugated antibody-drug-conjugate structure using multidimensional chromatography.Use of antibodies and immunoconjugates for the therapy of more accessible cancers.Microtubule-associated protein tau facilitates the targeted killing of proliferating cancer cells in vitro and in a xenograft mouse tumour model in vivo.In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate.Site-specific antibody drug conjugates for cancer therapyAntibody-maytansinoid conjugates for the treatment of myeloma.Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1).Micro- and nanocarrier-mediated lung targeting.Investigational antibody-drug conjugates for hematological malignancies.Analytical methods for physicochemical characterization of antibody drug conjugatesNovel strategies for immunotherapy in multiple myeloma: previous experience and future directions.Optimising the delivery of tubulin targeting agents through antibody conjugation.ADME of antibody-maytansinoid conjugatesMonoclonal antibody-based immunotherapy for multiple myeloma.Targeting CD30 in anaplastic large cell lymphoma.Targeted drug delivery for cancer therapy: the other side of antibodies.Drug-conjugated antibodies for the treatment of cancer.Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma.Tumour vasculature targeting agents in hybrid/conjugate drugs.Gastric cancer stem cells: therapeutic targets.How validated receptor occupancy flow cytometry assays can impact decisions and support drug development.Continuous counter-current chromatography for capture and polishing steps in biopharmaceutical production.Synthesis, drug release, and biological evaluation of new anticancer drug-bioconjugates containing somatostatin backbone cyclic analog as a targeting moiety.
P2860
Q24624489-8025BFE9-9A9E-44C0-98A1-1F97F478F234Q24632855-7573FEBF-5ABB-442D-84BF-37FD61A3092EQ26800175-9CEBC0C2-C044-4B74-AFA0-C21C48F3D890Q27007486-6E04FB6C-0248-450B-A473-26090D398E64Q28270261-6B9D77E5-1C8A-4559-93BF-0481C0B2B658Q28550176-4D9F782C-44C9-4CB9-8C59-A33B4E707FE5Q33309341-FC9B050D-7C40-4067-A463-B79467B11B67Q33409083-93ADDF7A-8069-4B51-9B4C-4E28661FA214Q33944427-19F813D8-D0AB-4FD0-80E8-F49AF806AB5AQ34089152-B5A16FBB-1C3E-4D30-A449-C0994BF7F9ACQ34177359-658DFA62-1CAF-4FAC-97F2-4605955906FCQ36108943-60F9E24A-D165-462F-8C2D-4F8E184E3830Q36307689-0DCD5E76-3F83-4DC8-8124-D67D8FC65CDFQ36715285-65302896-2DB0-47EA-9E72-970625265F4DQ36732080-20A524F5-758E-4C7E-87D4-310994F41387Q37042256-4A4624CE-9BF5-4BB0-BA8D-1BF4AA417872Q37055023-ACED9BA0-FA8F-4AFF-AA7A-9DB6F69F8514Q37138223-941BF912-3F96-4C7C-8191-477541CB04F6Q37174938-7BBE671C-1164-41B7-8DF7-1425169E3994Q37182201-CF8EFE24-4098-4166-BE0D-432E2676EBC6Q37327321-F58765EC-696A-4FB3-8779-865ABDABE7BFQ37593705-1AC469C4-1395-4523-8C28-093C3338A18FQ37672881-CF4856BB-9848-4297-BDA3-ED75F6734D8FQ37680178-AD3D6E49-26DA-4260-B452-B5C2D43AF4F3Q37766234-D5F37586-45E2-44E4-B161-73B9AC0B6A9EQ37818256-303381A3-7A32-4531-8C70-19EDAB5BDC1CQ37858385-4271E715-70D5-410B-84CF-D036CFBACBA0Q38014834-2F056283-268D-44CF-BB96-F64E27361844Q38024991-A2D586DC-5CE6-4783-A70E-7D5FBCD63C4AQ38033114-8F826A8D-91DB-4348-B044-0EBC382B2C9CQ38050507-6AE8D17C-E486-4FDC-B2B8-DAF59B333ADDQ38052082-C1E3587B-D429-4BDC-859A-36D411E26650Q38058816-3D4E7F45-2319-4052-86F9-3C89940369DBQ38061647-3D220D62-A464-471B-803C-D7FE9D369902Q38090691-05F2380B-F0D3-44F8-B0E6-7E90862B4CCAQ38094627-ECB5384C-2C07-44EC-A174-CDA47D826B20Q38096903-F58FEFBB-CD5C-47E6-A304-A7AFFE06FC94Q38579129-ED21BDFF-29CC-4717-B3ED-A086F00949D8Q38845449-AB166616-23C8-4678-8B26-44F90F491C92Q38865705-18F9E079-F644-4CF3-B03F-FEAC31115CE5
P2860
Drug-conjugated monoclonal antibodies for the treatment of cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Drug-conjugated monoclonal antibodies for the treatment of cancer.
@ast
Drug-conjugated monoclonal antibodies for the treatment of cancer.
@en
type
label
Drug-conjugated monoclonal antibodies for the treatment of cancer.
@ast
Drug-conjugated monoclonal antibodies for the treatment of cancer.
@en
prefLabel
Drug-conjugated monoclonal antibodies for the treatment of cancer.
@ast
Drug-conjugated monoclonal antibodies for the treatment of cancer.
@en
P1476
Drug-conjugated monoclonal antibodies for the treatment of cancer.
@en
P2093
John M Lambert
P304
P356
10.1016/J.COPH.2005.04.017
P577
2005-10-01T00:00:00Z